Affiliation:
1. Medical Institute of Continuing Education, MSUFP; Institute of Clinical and Economic Assessment and Pharmacoeconomics, JSC
2. Medical Institute of Continuing Education, MSUFP; FSAEI HE I.M. Sechenov First MSMU MOH Russia; State Budgetary Institution of the Moscow region “Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry”
3. Medical Institute of Continuing Education, MSUFP; Institute of Clinical and Economic Assessment and Pharmacoeconomics, JSC; State Budgetary Institution of the Moscow region “Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry”
Abstract
Rhinosinusitis with nasal polyps (RwNP) is a one of most common comorbidities in asthma and contrariwise and can lead to exacerbation of severe asthma (SA). Dupilumab is a perspective medicine for treatment of both, because it decreases exacerbations and prevents of a necessity of surgeon. Economics aspects of dupilumab treatment in RwNP + SA are not examined yet. Thus aim of this study was evaluation of social-economic burden of RwNP + SA in the Russian Federation and dupilumab influence on it. Materials and methods. Direct medical (cost of medicines, treatment in outpatients department and in hospital, including surgery and rate of exacerbations per year) and non-medical (payment for temporary and stable disability) and indirect costs (GDP loses) in RwNP + SA patients have been evaluated. Medical cure of a patient with RwNP + SA was created according to survey of experts from different regions of Russia. Modelling of expenditures was prepared on all calculated cohort of potential patients with RwNP + SA from “State” position and growing approach. Results. Expenditures for cure of one patient with RwNP were as 234 217,71 RUR/year. Weighted average costs for one patient with RwNP + SA were 1 881 883,39 RUR, and mostly were associated with indirect costs. Dupilumab can decrease expenditures for one patient with RwNP + SA till 1 593 162,87 RUR (on 15,3 %) annually. Potential cohort with RwNP + SA has been estimated above 39 thousand patients. Total economic burden of RwNP + SA in Russia were estimated as 1,7 bln RUR. Dupilumab usage in patients with RwNP + SA fixed in Register can help decrease economic burden on 259 mln RUR annually. Hidden economic burden of comorbidity can reach 73,4 bln RUR (for all calculated / modelled cohort of patients with RwNP + SA), dupilumab saves 11,3 bln RUR annually in this scenario. Conclusion. Comorbid pathology — RwNP+SA has a sufficient social-economic burden in Russia, that could be decreased by modern biologic drugs, in particular, with dupilumab.
Reference36 articles.
1. Zyryanov S. K., D'yakov I. N., Karpov O. I. Modelirovanie vliyaniya immunobiologicheskikh preparatov na ekonomicheskoe bremya tyazheloi bronkhial'noi astmy. Kachestvennaya klinicheskaya praktika. 2019;(3):4–12 [Zyryanov SK, Dyakov IN, Karpov OI. Modeling of the impact of biological drugs in the economic burden of severe asthma. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2019;(3):4–12. (In Russ).]. doi: 10.24411/2588-0519-2019-10078
2. Krysanov I. S., Krysanova V. S., Karpov O. I., Ermakova V. Yu. Ekonomicheskoe bremya tyazheloi bronkhial'noi astmy i atopicheskogo dermatita i vliyanie na nego dupilumaba. Kachestvennaya klinicheskaya praktika. 2020;(3):15–26 [Krysanov IS, Krysanova VS, Karpov OI, Ermakova VYu. Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2020;(3):15–26. (In Russ).]. doi: 10.37489/2588-0519-2020-3-15-26
3. Krysanov I. S., Krysanova V. S., Ermakova V. Yu. Kliniko-ekonomicheskii analiz primeneniya preparata dupilumab pri tyazheloi bronkhial'noi astme. Kachestvennaya klinicheskaya praktika. 2020;(5):15–26 [Krysanov IS, Krysanova VS, Ermakova VYu. The clinical-economic analysis of Dupilumab in severe asthma. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2020;(5):15–26. (In Russ).]. doi: 10.37489/2588-0519-2020-5-15-26
4. Chichkova N. V. Bronkhial'naya astma i zabolevaniya polosti nosa i okolonosovykh pazukh: edinstvo patologicheskikh protsessov v dykhatel'noi sisteme. Russkii meditsinskii zhurnal. 2015;(18):1132–6 [Chichkova NV. Asthma and rhino diseases: a common of pathological processes. RMJ. 2015;(18):1132–6. (In Russ).].
5. Kurbacheva O. M., Dyneva M. E., Shilovskii I. P., Savlevich E. L., Kovchina V. I., Nikol'skii A. A., Savushkina E. Yu., Khaitov M. R. Polipoznyi rinosinusit v sochetanii s bronkhial'noi astmoi: klinicheskie osobennosti i kletochnaya kharakteristika lokal'nogo i sistemnogo vospaleniya. Rossiiskii allergologicheskii zhurnal. 2020;17(1):32–49. doi: 10.36691/RAJ.2020.17.1.004 [Kurbacheva OM, Dyneva ME, Shilovskii IP, Savlevich EL, Kovchina VI, Nikolskii AA, Savushkina EYu, Khaitov MR. Polypous rhinosinusitis in combination with bronchial asthma: clinical features and cellular characteristics of local and systemic inflammation. Russian journal of Allergy. 2020;17(1):32–49. (In Russ).]. doi: 10.36691/RAJ.2020.17.1.004
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献